Bhageria Industries Ltd

Bhageria Industries has a strong capital structure with a debt-to-equity ratio of 0.08, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.68, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's cash and equivalents are reported at -INR 1,000, and net cash is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Bhageria Industries reports a return on equity (ROE) of 7.24% and a return on assets (ROA) of 5.51%. These figures are below the typical thresholds for high-performing specialty chemical firms, indicating that the company is generating returns, but not at a level that would be considered exceptional within its industry. The company's revenue is distributed across four segments: Chemicals, Solar Power, Pharma, and Others. The Chemicals segment is the primary revenue driver, followed by Solar Power and Pharma. The Others segment includes trading and engineering, procurement, and construction services in the solar sector. Geographically, the company exports to a diverse set of countries, including Korea, Japan, Taiwan, China, Germany, Indonesia, Thailand, the United States, and other European and African countries. Looking at the growth trajectory, Bhageria Industries has demonstrated a consistent revenue stream, with a total revenue of INR 5,946.11 million in the latest reporting period. The company's outlook for the current fiscal year is positive, with expected growth in the Solar Power and Pharma segments. However, the growth in the Chemicals segment is expected to be moderate. The risk assessment for Bhageria Industries indicates a medium liquidity risk and a low dilution risk. The company's capital structure is relatively conservative, with a low debt-to-equity ratio and a manageable level of long-term debt. However, the negative net cash position and the potential for capital expenditure in the Solar Power segment could pose liquidity challenges in the near term. Recent events and filings have not indicated any significant changes in the company's operations or financial strategy. The company continues to focus on expanding its presence in the Solar Power and Pharma segments while maintaining its core Chemicals business.